Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - HC Wainwright dropped their FY2024 earnings estimates for shares of Sangamo Therapeutics in a report released on Monday, January 27th. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceutical company will post earnings of ($0.49) per share for the year, down from their previous estimate of ($0.43). HC Wainwright has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Sangamo Therapeutics' current full-year earnings is ($0.47) per share. HC Wainwright also issued estimates for Sangamo Therapeutics' Q4 2024 earnings at ($0.11) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at $0.01 EPS, FY2025 earnings at ($0.08) EPS, FY2026 earnings at ($0.17) EPS, FY2027 earnings at ($0.02) EPS, FY2028 earnings at $0.19 EPS and FY2029 earnings at $0.42 EPS.
Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.07. The firm had revenue of $49.41 million for the quarter, compared to the consensus estimate of $26.55 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. During the same period in the prior year, the business posted ($0.34) earnings per share.
Several other equities analysts have also commented on SGMO. Barclays upped their price target on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an "overweight" rating in a research report on Thursday, November 14th. Jefferies Financial Group dropped their price objective on Sangamo Therapeutics from $7.00 to $3.00 and set a "buy" rating for the company in a report on Tuesday, December 31st. StockNews.com cut Sangamo Therapeutics from a "buy" rating to a "hold" rating in a report on Tuesday, December 24th. Wells Fargo & Company reduced their price objective on Sangamo Therapeutics from $3.00 to $2.00 and set an "equal weight" rating on the stock in a research note on Tuesday, December 31st. Finally, Truist Financial dropped their target price on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating for the company in a research report on Thursday, January 23rd. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $5.17.
View Our Latest Stock Analysis on SGMO
Sangamo Therapeutics Stock Performance
Shares of SGMO stock remained flat at $1.13 during trading hours on Wednesday. 2,882,605 shares of the stock traded hands, compared to its average volume of 5,991,089. The business's 50-day moving average price is $1.76 and its two-hundred day moving average price is $1.33. Sangamo Therapeutics has a 1-year low of $0.30 and a 1-year high of $3.18. The stock has a market cap of $235.77 million, a price-to-earnings ratio of -1.51 and a beta of 1.29.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. Shelton Wealth Management LLC bought a new stake in shares of Sangamo Therapeutics in the 4th quarter worth about $29,000. Sageworth Trust Co bought a new stake in Sangamo Therapeutics during the fourth quarter valued at $61,000. Cubist Systematic Strategies LLC bought a new stake in Sangamo Therapeutics during the second quarter valued at $67,000. Meritage Portfolio Management raised its holdings in shares of Sangamo Therapeutics by 8.6% during the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company's stock worth $74,000 after purchasing an additional 6,740 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Sangamo Therapeutics in the 2nd quarter worth about $89,000. 56.93% of the stock is owned by institutional investors and hedge funds.
About Sangamo Therapeutics
(
Get Free Report)
Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.
See Also
Before you consider Sangamo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sangamo Therapeutics wasn't on the list.
While Sangamo Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
